OBJECTIVES: Boceprevir plus P/R has demonstrated a superior clinical profile, compared to P/R alone, in the treatment of genotype 1 chronic hepatitis C (G1-CHC) patients. The objective of this study was to evaluate the cost-effectiveness of BOC/P/R therapy for treatment naïve and treatment experienced G1-CHC patients in Greece. METHODS: A Markov-model simulating the quality-adjusted life years and corresponding costs of G1-CHC treatment provided the basis of the analyses. The BOC/P/R regimens recommended in the label for treatment naïve and treatment experienced patients were compared to P/R to calculate incremental costs and outcomes. The inputs for the model were derived from post-hoc subset analyses of SPRINT-2 and RESPOND-2 data. Resource use for patient monitoring and treatment of events was elicited via expert panel. Lifetime horizon with 3% discount rate was used and the perspective of analysis was third-party payers. RESULTS: BOC-based therapy was projected to reduce liver complications (decompensated cirrhosis, hepatocellular carcinoma, liver transplant and liver–related death) by 44% and 49-53% in treatment naïve and experienced patients, respectively, leading to corresponding gains of 0.87 and 1.25 QALYs per patient. Taking into account medication costs, treatment and management of events, the ICER for BOC-based therapy versus P/R were estimated at 10,003€/QALY and 10,852€/QALY for treatment naïve and experienced patients, respectively.  Extensive sensitivity analyses indicated that results were robust. CONCLUSIONS: Based on the results of this analysis, the addition of Boceprevir to P/R for treatment of G1 CHC patients can be a cost-effective treatment option in the Greek healthcare setting.